Comparison between Burger King IPO and Gland Pharma IPO.
Burger King IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Gland Pharma IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Burger King IPO is up to ₹810.00 Cr whereas the issue size of the Gland Pharma IPO is up to ₹6,479.55 Cr. The final issue price of Burger King IPO is ₹60.00 per share and of Gland Pharma IPO is ₹1,500.00 per share.
| Burger King IPO | Gland Pharma IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹1 per share |
| Issue Price (Lower) | ₹59.00 per share | ₹1,490.00 per share |
| Issue Price (Upper) | ₹60.00 per share | ₹1,500.00 per share |
| Issue Price (Final) | ₹60.00 per share | ₹1,500.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 250 shares | 10 shares |
| Fresh Issue Size | 7,50,00,000 shares | 83,33,333 shares |
| Fresh Issue Size (Amount) | up to ₹450.00 Cr | up to ₹1,250.00 Cr |
| OFS Issue Size | 6,00,00,000 shares | 3,48,63,635 shares |
| OFS Issue Size (Amount) | up to ₹360.00 Cr | up to ₹5,229.55 Cr |
| Issue Size Total | 13,50,00,000 shares | 4,31,96,968 shares |
| Issue Size Total (Amount) | up to ₹810.00 Cr | up to ₹6,479.55 Cr |
Burger King IPO opens on Dec 02, 2020, while Gland Pharma IPO opens on Nov 09, 2020. The closing date of Burger King IPO and Gland Pharma IPO is Dec 04, 2020, and Nov 11, 2020, respectively.
| Burger King IPO | Gland Pharma IPO | |
|---|---|---|
| Anchor Bid Date | Dec 01, 2020 | Nov 06, 2020 |
| Issue Open | Dec 02, 2020 | Nov 09, 2020 |
| Issue Close | Dec 04, 2020 | Nov 11, 2020 |
| Basis Of Allotment (Tentative) | Dec 09, 2020 | Nov 17, 2020 |
| Initiation of Refunds (Tentative) | Dec 10, 2020 | Nov 18, 2020 |
| Credit of Share (Tentative) | Dec 11, 2020 | Nov 19, 2020 |
| Listing date (Tentative) | Dec 14, 2020 | Nov 20, 2020 |
| Anchor Lockin End date 1 | Jan 08, 2021 | Dec 17, 2020 |
| Anchor Lockin End date 2 | Mar 09, 2021 | Feb 15, 2021 |
Burger King IPO P/E ratio is , as compared to Gland Pharma IPO P/E ratio of .
| Burger King IPO | Gland Pharma IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 99.39 | 74 | ||||
| Promoter Shareholding (Post-Issue) | 60.08 | 58 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹2289.93 Cr. | ₹24492.42 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Burger King IPO Retail Individual Investors (RII) are offered 1,35,00,000 shares while in Gland Pharma IPO retail investors are offered 1,35,00,000 shares. Qualified Institutional Buyers (QIB) are offered 4,05,00,000 shares in Burger King IPO and 86,39,394 shares in Gland Pharma IPO.
| Burger King IPO | Gland Pharma IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,07,50,000 shares | 1,29,59,089 shares |
| Market Maker Reservation | ||
| QIB | 4,05,00,000 shares | 86,39,394 shares |
| NII | 2,02,50,000 shares | 64,79,546 shares |
| RII | 1,35,00,000 shares | 1,51,18,939 shares |
| Employee | ||
| Others | ||
| Total | 13,50,00,000 shares | 4,31,96,968 shares |
Burger King IPO subscribed 156.65x in total, whereas Gland Pharma IPO subscribed 2.06x.
| Burger King IPO | Gland Pharma IPO | |
|---|---|---|
| QIB (times) | 86.64x | 6.40x |
| NII (times) | 354.11x | 0.51x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 68.15x | 0.24x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 156.65x | 2.06x |
